Horizontal bar chart showing McKesson’s fiscal Q1 2027 adjusted segment operating-profit variance versus Aug. 4 pre-print consensus. North American Pharmaceutical exceeded consensus by $86.8 million and Oncology & Multispecialty by $25.2 million. RxTS was in line, while Medical-Surgical Solutions missed by $52.1 million. The segment variances netted to a $59.9 million favorable result.